• English
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Executive Committee
    • Working Groups
      • Drug Assessment
      • Education
      • Therapeutics Letter
      • PharmacoEpidemiology
      • Quality Prescribing Working Group
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
  • Contact Us

What’s New

[116] New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?

[116] New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?

December 27, 2018 Therapeutics Letter 1 Comment

A new drug for cystic fibrosis (CF) that combines lumacaftor and ivacaftor (Orkambi), was approved by Health Canada (HC) in 2016 to treat people age 12 and older with the most frequent CF genetic mutation: homozygous F508 deletion of the cystic … Read More

Download
Share
[115] Cannabinoids for Chronic Pain

[115] Cannabinoids for Chronic Pain

November 22, 2018 Therapeutics Letter 4 Comments

Canada's parliament legalized the recreational use of herbal cannabis (marijuana) in October 2018. The well-publicized limitations of clinical research and well-recognized side effects such as cannabis intoxication have not deterred people from … Read More

Download
Share
30th Annual Best Science Medicine Course

30th Annual Best Science Medicine Course

March 20, 2018 Education

Friday, May 3, 2019 and Saturday, May 4, 2019 Fairmont Waterfront – 900 Canada Place Way, Vancouver, BC … Read More

[114] Shingrix: A New Vaccine for Shingles

[114] Shingrix: A New Vaccine for Shingles

October 10, 2018 Therapeutics Letter 11 Comments

Herpes zoster (HZ) or “shingles” occurs when the varicella zoster virus (VZV), lying latent in the sensory ganglia, becomes reactivated. An HZ outbreak typically presents as a vesicular skin eruption most characteristically forming a painful girdle … Read More

Download
Share
[113] How well do you know your anticholinergic (antimuscarinic) drugs?

[113] How well do you know your anticholinergic (antimuscarinic) drugs?

September 10, 2018 Therapeutics Letter 3 Comments

Anticholinergic drugs, prescribed for a variety of clinical conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “antimuscarinics,” such drugs specifically block muscarinic receptors for … Read More

Download
Share

Donation Button

Like what we do? Support our initiative.
Get involved or donate today.
Donate

Join the Conversation

Tweets by @Drug_Evidence
 

Unable to display Facebook posts.
Show error

Error: (#4) Application request limit reached
Type: OAuthException
Code: 4
Please refer to our Error Message Reference.

Therapeutics Initiative

Our mission is to provide physicians, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3

Office +1 604-822-0700

UBC logoISDB logo

Subscribe to TI

Not sure? Learn about the benefits

© 1994 - 2019 Therapeutics Initiative · Terms & Policies · TM